European Union - English - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - clostridium septicum toxoid; clostridium tetani toxoid; clostridium perfringens type d toxoid; clostridium novyi type b toxoid/cells; clostridium chauvoei toxoid/cells - clostridium septicum toxoid 0 vaccine; clostridium tetani toxoid 0 vaccine; clostridium perfringens type d toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; clostridium chauvoei toxoid/cells 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - gonadotrophin (gnrf poly albumin) - gonadotrophin (gnrf poly albumin) 0.3 thou iu/ml - endocrine agent (hormone)

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - dexamethasone - dexamethasone 2 g/litre - endocrine agent (hormone)

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - leptospira interrogans serovar hardjoprajitno; leptospira interrogans serovar pomona - leptospira interrogans serovar hardjoprajitno 0 vaccine; leptospira interrogans serovar pomona 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - gonadotrophin (gnrf poly albumin) - gonadotrophin (gnrf poly albumin) 1 thou iu/ml - endocrine agent (hormone)

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - cloprostenol sodium - cloprostenol sodium 0.25 g/litre - endocrine agent (hormone)

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - oxytetracycline - oxytetracycline 100 g/litre - antibiotic

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - cephalonium - cephalonium 83.3 g/kg - antibiotic

European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.